219 related articles for article (PubMed ID: 34857909)
1. Novel insights into the BAP1-inactivated melanocytic tumor.
Donati M; Martinek P; Steiner P; Grossmann P; Vanecek T; Kastnerova L; Kolm I; Baneckova M; Donati P; Kletskaya I; Kalmykova A; Feit J; Blasch P; Szilagyi D; Baldi A; Persichetti P; Crescenzi A; Michal M; Kazakov DV
Mod Pathol; 2022 May; 35(5):664-675. PubMed ID: 34857909
[TBL] [Abstract][Full Text] [Related]
2. RAF1 Gene Fusions as a Possible Driver Mechanism in Rare BAP1-Inactivated Melanocytic Tumors: A Report of 2 Cases.
Donati M; Martinek P; Kastnerova L; Persichetti P; Michal M; Kazakov DV
Am J Dermatopathol; 2020 Dec; 42(12):961-966. PubMed ID: 32769548
[TBL] [Abstract][Full Text] [Related]
3. Histomorphologic spectrum of germline-related and sporadic BAP1-inactivated melanocytic tumors.
Garfield EM; Walton KE; Quan VL; VandenBoom T; Zhang B; Kong BY; Isales MC; Panah E; Kim G; Gerami P
J Am Acad Dermatol; 2018 Sep; 79(3):525-534. PubMed ID: 29753057
[TBL] [Abstract][Full Text] [Related]
4. The morphologic spectrum of germline-mutated BAP1-inactivated melanocytic tumors includes lesions with conventional nevic melanocytes: A case report and review of literature.
Wysozan TR; Khelifa S; Turchan K; Alomari AK
J Cutan Pathol; 2019 Nov; 46(11):852-857. PubMed ID: 31206729
[TBL] [Abstract][Full Text] [Related]
5. Clinical and dermoscopic features of cutaneous BAP1-inactivated melanocytic tumors: Results of a multicenter case-control study by the International Dermoscopy Society.
Yélamos O; Navarrete-Dechent C; Marchetti MA; Rogers T; Apalla Z; Bahadoran P; Blázquez-Sánchez N; Busam K; Carrera C; Dusza SW; de la Fouchardière A; Ferrara G; Gerami P; Kittler H; Lallas A; Malvehy J; Millán-Cayetano JF; Nelson KC; Quan VL; Puig S; Stevens H; Thomas L; Marghoob AA
J Am Acad Dermatol; 2019 Jun; 80(6):1585-1593. PubMed ID: 30244062
[TBL] [Abstract][Full Text] [Related]
6. Combined BRAF(V600E)-positive melanocytic lesions with large epithelioid cells lacking BAP1 expression and conventional nevomelanocytes.
Busam KJ; Sung J; Wiesner T; von Deimling A; Jungbluth A
Am J Surg Pathol; 2013 Feb; 37(2):193-9. PubMed ID: 23026932
[TBL] [Abstract][Full Text] [Related]
7. A case of molecularly confirmed BAP1 inactivated melanocytic tumor with retention of immunohistochemical expression: A confounding factor.
Linos K; Atkinson AE; Yan S; Tsongalis GJ; Lefferts JA
J Cutan Pathol; 2020 May; 47(5):485-489. PubMed ID: 31891422
[TBL] [Abstract][Full Text] [Related]
8. A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expression.
Wiesner T; Murali R; Fried I; Cerroni L; Busam K; Kutzner H; Bastian BC
Am J Surg Pathol; 2012 Jun; 36(6):818-30. PubMed ID: 22367297
[TBL] [Abstract][Full Text] [Related]
9. BAP1-inactivated melanocytic tumor with preserved BAP1 expression? Morphology to the rescue!
Duncan LM; Tetzlaff MT
J Cutan Pathol; 2020 May; 47(5):459-461. PubMed ID: 32096236
[TBL] [Abstract][Full Text] [Related]
10. Multiple epithelioid Spitz nevi or tumors with loss of BAP1 expression: a clue to a hereditary tumor syndrome.
Busam KJ; Wanna M; Wiesner T
JAMA Dermatol; 2013 Mar; 149(3):335-9. PubMed ID: 23552620
[TBL] [Abstract][Full Text] [Related]
11. Germline BRCA1-associated protein 1 mutation presenting as BAP1 inactivated melanocytic nevi in a child of a father with fatal paraganglioma.
Watchorn RE; Calonje E; Taibjee SM
Pediatr Dermatol; 2018 Sep; 35(5):e316-e318. PubMed ID: 29974497
[TBL] [Abstract][Full Text] [Related]
12. BAP1-inactivated melanocytic tumors show prominent centrosome amplification and associated loss of primary cilia.
Ye J; Sheahon KM; LeBoit PE; McCalmont TH; Lang UE
J Cutan Pathol; 2021 Nov; 48(11):1353-1360. PubMed ID: 34085298
[TBL] [Abstract][Full Text] [Related]
13. NRAS-mutated melanocytic BAP1-associated intradermal tumor (MBAIT): a case report.
Blokx WA; Rabold K; Bovenschen HJ; Ligtenberg MJ; Mensenkamp AR; van Lijnschoten G; van Zelst-Stams WA; Groenen PJ
Virchows Arch; 2015 Jan; 466(1):117-21. PubMed ID: 25342144
[TBL] [Abstract][Full Text] [Related]
14. BAP1 and BRAFV600E expression in benign and malignant melanocytic proliferations.
Piris A; Mihm MC; Hoang MP
Hum Pathol; 2015 Feb; 46(2):239-45. PubMed ID: 25479927
[TBL] [Abstract][Full Text] [Related]
15. Germline mutations in BAP1 predispose to melanocytic tumors.
Wiesner T; Obenauf AC; Murali R; Fried I; Griewank KG; Ulz P; Windpassinger C; Wackernagel W; Loy S; Wolf I; Viale A; Lash AE; Pirun M; Socci ND; Rütten A; Palmedo G; Abramson D; Offit K; Ott A; Becker JC; Cerroni L; Kutzner H; Bastian BC; Speicher MR
Nat Genet; 2011 Aug; 43(10):1018-21. PubMed ID: 21874003
[TBL] [Abstract][Full Text] [Related]
16. BAP1-deficient and VE1-negative atypical Spitz tumor.
Requena C; Sanz V; Nagore E; García-Casado Z; Rubio L; Guillén C; Kutzner H
J Cutan Pathol; 2015 Aug; 42(8):564-7. PubMed ID: 25953246
[TBL] [Abstract][Full Text] [Related]
17. BRCA1-associated protein (BAP1)-inactivated melanocytic tumors.
Zhang AJ; Rush PS; Tsao H; Duncan LM
J Cutan Pathol; 2019 Dec; 46(12):965-972. PubMed ID: 31233225
[TBL] [Abstract][Full Text] [Related]
18. BAP1-Inactivated Melanoma Arising From BAP1-Inactivated Melanocytic Tumor in a Patient With BAP1 Germline Mutation: A Case Report and Review of the Literature.
Donati M; Šteiner P; Kazakov DV
Am J Dermatopathol; 2023 Feb; 45(2):117-122. PubMed ID: 36669076
[TBL] [Abstract][Full Text] [Related]
19. Genomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapy.
Wiesner T; Kutzner H; Cerroni L; Mihm MC; Busam KJ; Murali R
Pathology; 2016 Feb; 48(2):113-31. PubMed ID: 27020384
[TBL] [Abstract][Full Text] [Related]
20. Histomorphologic spectrum of BAP1 negative melanocytic neoplasms in a family with BAP1-associated cancer susceptibility syndrome.
Marušić Z; Buljan M; Busam KJ
J Cutan Pathol; 2015 Jun; 42(6):406-12. PubMed ID: 25902915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]